Claims
- 1. A compound of formula: ##STR9## and its pharmaceutically acceptable salts which are nontoxic, in which R.sub.1 represents polyfluoroalkoxy, and R.sub.2 represents pyridylthioalkyl, pyridylalkylthioalkyl, pyridylsulphinylalkyl, or pyridylalkylsulphinylalkyl, the said slkyl and alkoxy portions containing 1 to 4 carbon atoms each in a straight or branched chain.
- 2. A compound according to claim 1, in which R.sub.1 represents trifluoromethoxy, pentafluoroethoxy, 2,2,2-trifluoroethoxy, 1,1,2,2-tetrafluoroethoxy or 2,2,3,3,3-pentafluoropropoxy.
- 3. A pharmaceutical composition which comprises, as active principle, at least one compound according to claim 1, or a salt of such a compound with an inorganic or organic acid, and a compatible pharmaceutically acceptable carrier.
- 4. A method for the treatment of a medical condition associated with the effects of glutamate which comprises administering to a subject in need of such treatment an amount of a compound according to claim 1, or salt thereof sufficient to inhibit such effects at least partially.
- 5. A compound as claimed in claim 1 which is 2-imino-3-6-trifluoromethoxybenzothiazoline or its addition salts.
Priority Claims (2)
Number |
Date |
Country |
Kind |
88 16547 |
Dec 1988 |
FRX |
|
89 09482 |
Jul 1989 |
FRX |
|
Parent Case Info
This is a Continuation X Division of U.S. application Ser. No. 449,810, filed Dec. 13, 1989, now U.S. Pat. No. 4,980,356.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4929623 |
Abe et al. |
May 1990 |
|